from TetraKit Technologies
January 20, 2023
Our CEO, Andreas Jensen, will present at BioSeed in London, UK. Please reach us if you are interested in learning more about our universal labelling platform for theranostics and how it can be applied in your drug development programs. Schedule a meeting with Andreas Ingemann Jensen, PhD Pharm, by contacting him directly.
See you on Monday!
December 31, 2022
As we start a new year, it is a time for reflection and setting new goals. The new year is a chance to leave the past behind and look toward the future with hope and determination. It is an opportunity to start fresh and make positive changes in our lives. I hope that this new year brings you joy, health, and prosperity and that you are able to achieve all that you set out to do. Happy New Year!Read more
December 9, 2022
We are happy to announce a Ph.D. fellowship collaboration with Dept. of Drug Design and Pharmacology (ILF), University of Copenhagen. Welcome to apply via the Faculty of Health and Medical Sciences, https://healthsciences.ku.dk/
#university #collaboration #health #phd
Chief Executive Officer
“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”
Chief Scientific Officer
“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”